Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project

Jacek Niklinski; Adam Kretowski; Marcin Moniuszko; Joanna Reszec; Anna Michalska-Falkowska; Magdalena Niemira; Michal Ciborowski; Radoslaw Charkiewicz; Dorota Jurgilewicz; Miroslaw Kozlowski; Rodryg Ramlau; Cezary Piwkowski; Miroslaw Kwasniewski; Monika Kaczmarek; Andrzej Ciereszko; Tomasz Wasniewski; Robert Mroz; Wojciech Naumnik; Ewa Sierko; Magdalena Paczkowska; Joanna Kisluk; Anetta Sulewska; Adam Cybulski; Zenon Mariak; Boguslaw Kedra; Jacek Szamatowicz; Paweł Kurzawa; Lukasz Minarowski; Angelika Edyta Charkiewicz; Barbara Mroczko; Jolanta Malyszko; Christian Manegold; Lothar Pilz; Heike Allgayer; Mohammed L Abba; Hartmut Juhl; Frauke Koch; MOBIT Study Group

doi:10.1016/j.advms.2017.05.002

Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project

Adv Med Sci. 2017 Sep;62(2):405-413. doi: 10.1016/j.advms.2017.05.002. Epub 2017 Jun 21.

Authors

Jacek Niklinski¹, Adam Kretowski², Marcin Moniuszko³, Joanna Reszec⁴, Anna Michalska-Falkowska⁵, Magdalena Niemira², Michal Ciborowski², Radoslaw Charkiewicz⁵, Dorota Jurgilewicz⁶, Miroslaw Kozlowski⁷, Rodryg Ramlau⁸, Cezary Piwkowski⁹, Miroslaw Kwasniewski¹⁰, Monika Kaczmarek¹¹, Andrzej Ciereszko¹¹, Tomasz Wasniewski¹², Robert Mroz¹³, Wojciech Naumnik¹⁴, Ewa Sierko¹⁵, Magdalena Paczkowska², Joanna Kisluk⁵, Anetta Sulewska⁵, Adam Cybulski⁷, Zenon Mariak¹⁶, Boguslaw Kedra¹⁷, Jacek Szamatowicz¹⁸, Paweł Kurzawa¹⁹, Lukasz Minarowski²⁰, Angelika Edyta Charkiewicz²¹, Barbara Mroczko²², Jolanta Malyszko²³, Christian Manegold²⁴, Lothar Pilz²⁴, Heike Allgayer²⁵, Mohammed L Abba²⁶, Hartmut Juhl²⁷, Frauke Koch²⁷; MOBIT Study Group

Affiliations

¹ Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland. Electronic address: [email protected].
² Center of Clinical Research, Medical University of Bialystok, Bialystok, Poland.
³ Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.
⁴ Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland.
⁵ Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland.
⁶ Laboratory of Molecular Imaging and Technology Development, Medical University of Bialystok, Bialystok, Poland.
⁷ Department of Thoracic Surgery, Medical University of Bialystok, Bialystok, Poland.
⁸ Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland.
⁹ Department of Thoracic Surgery, Poznan University of Medical Sciences, Poznan, Poland.
¹⁰ Center of Bioinformatics and Data Analysis, Medical University of Bialystok, Bialystok, Poland.
¹¹ Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Olsztyn, Poland.
¹² Department of Gynecologic Oncology, Provincial Specialist Hospital in Olsztyn, Olsztyn, Poland.
¹³ Second Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, Poland.
¹⁴ First Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, Poland.
¹⁵ Department of Oncology, Medical University of Bialystok, Bialystok, Poland.
¹⁶ Department of Neurosurgery, Medical University of Bialystok, Bialystok, Poland.
¹⁷ Second Department of General and Gastroenterological Surgery, Medical University of Bialystok, Bialystok, Poland.
¹⁸ Department of Gynecology and Gynecologic Oncology, Medical University of Bialystok, Bialystok, Poland.
¹⁹ Chair of Clinical Pathomorphology, Poznan University of Medical Sciences, Poznan, Poland.
²⁰ First Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Bialystok, Poland; First Department of Lung Diseases and Chemotherapy of Respiratory Neoplasms, University Teaching Hospital, Bialystok, Poland.
²¹ Department of Public Health, Medical University of Bialystok, Bialystok, Poland.
²² Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland.
²³ Second Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland.
²⁴ Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland; Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
²⁵ Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland; Department of Experimental Surgery - Cancer Metastasis, Medical Faculty Mannheim, Ruprecht Karls University of Heidelberg and Center for Biomedicine and Medical Technology Mannheim (CBTM), Mannheim, Germany.
²⁶ Department of Experimental Surgery - Cancer Metastasis, Medical Faculty Mannheim, Ruprecht Karls University of Heidelberg and Center for Biomedicine and Medical Technology Mannheim (CBTM), Mannheim, Germany.
²⁷ Indivumed GmbH, Falkenreid 88, Hamburg, Germany.

PMID: 28646744
DOI: 10.1016/j.advms.2017.05.002

Abstract

Personalized and precision medicine is gaining recognition due to the limitations by standard diagnosis and treatment; many areas of medicine, from cancer to psychiatry, are moving towards tailored and individualized treatment for patients based on their clinical characteristics and genetic signatures as well as novel imaging techniques. Advances in whole genome sequencing have led to identification of genes involved in a variety of diseases. Moreover, biomarkers indicating severity of disease or susceptibility to treatment are increasingly being characterized. The continued identification of new genes and biomarkers specific to disease subtypes and individual patients is essential and inevitable for translation into personalized medicine, in estimating both, disease risk and response to therapy. Taking into consideration the mostly unsolved necessity of tailored therapy in oncology the innovative project MOBIT (molecular biomarkers for individualized therapy) was designed. The aims of the project are: (i) establishing integrative management of precise tumor diagnosis and therapy including systematic biobanking, novel imaging techniques, and advanced molecular analysis by collecting comprehensive tumor tissues, liquid biopsies (whole blood, serum, plasma), and urine specimens (supernatant; sediment) as well as (ii) developing personalized lung cancer diagnostics based on tumor heterogeneity and integrated genomics, transcriptomics, metabolomics, and radiomics PET/MRI analysis. It will consist of 5 work packages. In this paper the rationale of the Polish MOBIT project as well as its design is presented. (iii) The project is to draw interest in and to invite national and international, private and public, preclinical and clinical initiatives to establish individualized and precise procedures for integrating novel targeted therapies and advanced imaging techniques.

Keywords: Biobanking; Lung Cancer; Omics; Personalized medicine; Radiomics.

MeSH terms

Biological Specimen Banks*
Biomarkers, Tumor / analysis*
Humans
Metabolome
Molecular Imaging*
Molecular Targeted Therapy*
Neoplasms / diagnosis*
Neoplasms / therapy*
Precision Medicine*
Predictive Value of Tests
Proteome

Substances

Biomarkers, Tumor
Proteome